Lantheus Holdings (NASDAQ: LNTH) and Natera (NASDAQ:NTRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for Lantheus Holdings and Natera, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus Holdings 0 1 3 0 2.75
Natera 0 0 4 0 3.00

Lantheus Holdings currently has a consensus target price of $18.75, indicating a potential downside of 2.09%. Natera has a consensus target price of $15.75, indicating a potential upside of 48.31%. Given Natera’s stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Lantheus Holdings.

Earnings & Valuation

This table compares Lantheus Holdings and Natera’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lantheus Holdings $317.61 million 2.25 $75.23 million $0.72 26.60
Natera $203.71 million 2.76 -$119.53 million ($2.44) -4.35

Lantheus Holdings has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Lantheus Holdings, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lantheus Holdings and Natera’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lantheus Holdings 8.44% -37.47% 15.16%
Natera -62.64% -119.47% -60.86%

Risk & Volatility

Lantheus Holdings has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Natera has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

Insider & Institutional Ownership

66.3% of Lantheus Holdings shares are owned by institutional investors. Comparatively, 59.7% of Natera shares are owned by institutional investors. 2.3% of Lantheus Holdings shares are owned by insiders. Comparatively, 12.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Lantheus Holdings beats Natera on 7 of the 13 factors compared between the two stocks.

About Lantheus Holdings

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

About Natera

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.